Lucia Septién was appointed Chief Medical Officer in July 2016 and is responsible for the Company’s clinical development programs, medical affairs, global safety and medical operations. She also has a mission to accelerate the development of Viaskin product candidates. Dr. Septién is a member of the Executive Committee. She has more than 20 years of experience in the pharmaceutical industry. Prior to joining DBV, Dr. Septién was Vice President, Global Neurosciences at Ipsen, responsible for the Medical Strategy of the Botulinum Toxin portfolio. Prior to Ipsen, Dr. Septién served as Vice President of the Specialty Care Business Unit, Europe, at Pfizer. Before that, she served at Wyeth Pharma as Assistant Vice President, Global Neuroscience. Dr. Septién earned her medical degree at the National University of Mexico City, specializing in Psychiatry. She completed her post-graduate training in Nuclear Medicine at the Commisariat de l’Energie Atomique in Saclay, France.